文献速递关节外科运动医学

髌股关节置换术短期翻修风险高:八大数据登记系统分析

Short-term Revision Risk of Patellofemoral Arthroplasty Is High: An Analysis from Eight Large Arthroplasty Registries.
PubMed 文献 · Clin Orthop Relat Res · 2020-01-01

该研究整合澳大利亚、新西兰、加拿大、瑞典、芬兰、挪威、荷兰和美国八个关节登记系统2000年至2016年的数据,共纳入6784例髌股关节置换术(PFA)。PFA占所有初次膝关节置换不足1%,患者平均年龄50至60岁、女性居多。所有登记系统均显示高翻修率,5年累积翻修率从挪威8.0%(95%CI 4.5至11.5)到荷兰18.1%(95%CI 15.5至20.7),最常见翻修原因为疾病进展(42%),83%翻修为全膝关节置换术(TKA)。

要点

  • PFA占初次膝关节置换不足1%,患者平均年龄50至60岁、女性居多。
  • 5年累积翻修率挪威8.0%(95%CI 4.5至11.5)至荷兰18.1%(95%CI 15.5至20.7)。
  • 最常见翻修原因为疾病进展(42%),83%翻修为TKA。

核心结论

  • 所有登记系统中PFA翻修风险均高于同期报道的TKA翻修风险三倍以上。
  • PFA生存率与已不再使用的金属对金属常规髋关节置换术相似。
  • 尽管PFA可能有潜在功能获益,但一致且惊人的高翻修率应引起关注,尤其该手术常用于较年轻患者。

研究设计与样本

  • 数据包括患者人口学特征、植入物使用、全因翻修率(以累积翻修百分比CPR确定)及翻修原因和类型。
  • 证据等级为III级,治疗性研究。

主要发现

  • 共6784例PFA,在所有登记系统中PFA占初次膝关节置换不足1%。
  • 患者人口学特征各国可比,女性多于男性,平均年龄50至60岁。
  • 所有登记系统均显示高翻修率,5年全因CPR从挪威8.0%(95%CI 4.5至11.5)到荷兰18.1%(95%CI 15.5至20.7)。
  • 最常见翻修原因为疾病进展(42%,434/1034)。
  • 大多数PFA(83%,810/980)翻修为TKA。

临床怎么用

  • 临床医生应知晓PFA短期翻修风险高,尤其在较年轻患者中使用时需谨慎评估。
  • 术后随访应关注疾病进展,因其为最常见翻修原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patellofemoral arthroplasty (PFA) is one option for the treatment of isolated patellofemoral osteoarthritis, but there are limited data regarding the procedure and results. Because isolated patellofemoral arthritis is relatively uncommon, available case series generally are small, and even within national registries, sample sizes are limited. Combining data from multiple registries may aid in assessing worldwide PFA usage and survivorship. QUESTIONS/PURPOSES: We combined and compared data from multiple large arthroplasty registries worldwide to ask: (1) What proportion of patients undergoing primary knee arthroplasty have PFA? (2) What are the patient and prosthesis characteristics associated with PFA in common practice, as reflected in registries? (3) What is the survivorship free from revision of PFA and what are the reasons for and types of revisions? METHODS: Data were provided by eight registries that are members of the International Society of Arthroplasty Registries (ISAR) who agreed to share aggregate data: Australia, New Zealand, Canada, Sweden, Finland, Norway, the Netherlands, and the United States. De-identified data were obtained for PFA performed from either the beginning of year 2000, or the earliest recorded implantation date after that in each individual registry when PFA data collection commenced, up to December 31, 2016. This included patient demographics, implant use, all-cause revision rate (determined by cumulative percent revision [CPR]), and reasons for and type of revision. RESULTS: During the data collection period, 6784 PFAs were performed in the eight countries. PFAs comprised less than 1% of primary knee replacements in all registries. Patient demographics were comparable in all countries. Patients were generally more likely to be women than men, and the mean age ranged from 50 years to 60 years. All registries showed a high rate of revision for PFA. The 5-year CPR for any reason ranged from 8.0% (95% CI 4.5 to 11.5) in Norway to 18.1% (95% CI 15.5 to 20.7) in the Netherlands. The most common reason for revision across all countries was disease progression (42%, 434 of 1034). Most PFAs (83%, 810 of 980) were revised to a TKA. CONCLUSIONS: The revision risk of PFA in all registries surveyed was more than three times higher than the reported revision risk of TKA at the same times. The survivorship of PFA is similar to that of the no-longer-used procedure of metal-on-metal conventional hip replacement. Although there may be potential functional benefits from PFA, these findings of consistent and alarmingly high rates of revision should create concern, particularly as this procedure is often used in younger patients. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Lewis PL, Tudor F, Lorimer M, et al. Short-term Revision Risk of Patellofemoral Arthroplasty Is High: An Analysis from Eight Large Arthroplasty Registries. Clin Orthop Relat Res. 2020. PMID: 32348089. doi:10.1097/CORR.0000000000001268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。